| pubmed-article:15917651 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15917651 | lifeskim:mentions | umls-concept:C0597032 | lld:lifeskim |
| pubmed-article:15917651 | lifeskim:mentions | umls-concept:C0302600 | lld:lifeskim |
| pubmed-article:15917651 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:15917651 | lifeskim:mentions | umls-concept:C1136340 | lld:lifeskim |
| pubmed-article:15917651 | lifeskim:mentions | umls-concept:C0018284 | lld:lifeskim |
| pubmed-article:15917651 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:15917651 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15917651 | pubmed:dateCreated | 2005-8-12 | lld:pubmed |
| pubmed-article:15917651 | pubmed:abstractText | The Semaphorins are a large family of transmembrane, GPI-anchored and secreted proteins that play an important role in neuronal and endothelial cell guidance. A human gene related to the class 6 Semaphorin family, Semaphorin 6A-1 (Sema 6A-1) was identified by homology-based genomic mining. Recent implication of Sema 3 family members in tumor angiogenesis and our expression analysis of Sema 6A-1 suggested that class 6 Semaphorin might effect tumor neovascularization. The mRNA expression of Sema 6A-1 was elevated in several renal tumor tissue samples relative to adjacent nontumor tissue samples from the same patient. Sema 6A-1 transcript was also expressed in the majority of renal clear cell carcinoma (RCC) cell lines and to a lesser extent in endothelial cells. To test the role of Sema 6A-1 in tumor angiogenesis, we engineered, expressed and purified the Sema 6A-1 soluble extracellular domain (Sema-ECD). The purified Sema-ECD was screened in a variety of endothelial cell-based assays both in vitro and in vivo. In vitro, Sema-ECD blocked VEGF-mediated endothelial cell migration. These effects were explained in part by our observation in endothelial cells that Sema-ECD inhibited VEGF-mediated Src, FAK and ERK phosphorylation. In vivo, mouse Matrigel assays demonstrated that the intraperitoneal administration of recombinant Sema-ECD inhibited both bFGF/VEGF and tumor cell line-induced neovascularization. These findings reveal a novel therapeutic utility for Sema 6A-1 (Sema-ECD) as an inhibitor of growth factor as well as tumor-induced angiogenesis. | lld:pubmed |
| pubmed-article:15917651 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15917651 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15917651 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15917651 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15917651 | pubmed:issn | 1538-4047 | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:WuFrankF | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:AlvarezEnriqu... | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:LaRochelleWil... | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:LichensteinHe... | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:DhanabalMohan... | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:BoldogFerenc... | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:McQueeneyKell... | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:HackettCraigC | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:ShenoySureshS | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:JeffersMikeM | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:MacDougallJoh... | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:KhramtsovNiko... | lld:pubmed |
| pubmed-article:15917651 | pubmed:author | pubmed-author:WeinerJamiJ | lld:pubmed |
| pubmed-article:15917651 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15917651 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:15917651 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15917651 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15917651 | pubmed:pagination | 659-68 | lld:pubmed |
| pubmed-article:15917651 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:meshHeading | pubmed-meshheading:15917651... | lld:pubmed |
| pubmed-article:15917651 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15917651 | pubmed:articleTitle | Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis. | lld:pubmed |
| pubmed-article:15917651 | pubmed:affiliation | CuraGen Corporation, Branford, Connecticut, USA. mdhanabal@curagen.com | lld:pubmed |
| pubmed-article:15917651 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15917651 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15917651 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15917651 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15917651 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15917651 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15917651 | lld:pubmed |
